Schrödinger (NASDAQ:SDGR) Shares Up 8.1% – Should You Buy?

Schrödinger, Inc. (NASDAQ:SDGR) was up 8.1% on Monday . The stock traded as high as $26.56 and last traded at $26.48. Approximately 731,559 shares were traded during mid-day trading, a decline of 8% from the average daily volume of 795,331 shares. The stock had previously closed at $24.49.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on SDGR shares. KeyCorp raised their price target on Schrödinger from $25.00 to $27.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Piper Sandler decreased their target price on Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Schrödinger currently has a consensus rating of “Buy” and an average price target of $32.29.

Schrödinger Stock Performance

The firm has a fifty day simple moving average of $21.98 and a 200 day simple moving average of $20.84. The company has a market capitalization of $1.87 billion, a PE ratio of -10.94 and a beta of 1.77.

Schrödinger (NASDAQ:SDGR) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.20). The firm had revenue of $88.32 million for the quarter, compared to analysts’ expectations of $83.20 million. Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. Research analysts expect that Schrödinger, Inc. will post -2.37 EPS for the current fiscal year.

Insider Buying and Selling at Schrödinger

In other Schrödinger news, CFO Geoffrey Craig Porges sold 5,491 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $21.76, for a total transaction of $119,484.16. Following the completion of the sale, the chief financial officer now owns 27,544 shares in the company, valued at $599,357.44. This represents a 16.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Karen Akinsanya sold 16,723 shares of Schrödinger stock in a transaction on Monday, April 14th. The shares were sold at an average price of $25.09, for a total value of $419,580.07. Following the completion of the transaction, the insider now owns 15,625 shares in the company, valued at $392,031.25. This represents a 51.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Schrödinger

A number of hedge funds have recently made changes to their positions in the stock. Point72 Hong Kong Ltd purchased a new position in Schrödinger in the fourth quarter valued at about $27,000. Paradigm Asset Management Co. LLC bought a new stake in shares of Schrödinger in the 4th quarter valued at about $50,000. GAMMA Investing LLC grew its position in shares of Schrödinger by 87.5% in the 4th quarter. GAMMA Investing LLC now owns 2,796 shares of the company’s stock worth $54,000 after buying an additional 1,305 shares during the last quarter. KBC Group NV raised its stake in shares of Schrödinger by 73.9% during the 4th quarter. KBC Group NV now owns 4,361 shares of the company’s stock worth $84,000 after acquiring an additional 1,853 shares in the last quarter. Finally, Bayesian Capital Management LP purchased a new stake in Schrödinger during the fourth quarter valued at approximately $199,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.